Cancer Family
Childhood Digestive System Neoplasm
CI-CAN-00000125Explore in graph →
PediatricNon-malignant24 active trials
- NCIt
- C189869
Loading cancer entity…
Cancer Family
CI-CAN-00000125Explore in graph →
Clinical trials
70 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07656740 | Non-Operative Management and Following Immunotherapy for Colorectal Cancer and Other GI Cancers(NOMIC) | not yet recruiting | — | 50 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07211230 | Collagenase Biobank Study | not yet recruiting | — | 107 | University of ChicagoOTHER | 1 | Apr 9, 2026 |
| clinicaltrials |
| NCT07474025 | Integrating Peritoneal Histological Growth Patterns Into Preoperative Decision-Making for Colorectal Peritoneal Metastses | not yet recruiting | — | 30 | Jules Bordet InstituteOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT06943794 | Eradication of Helicobacter Pylori Subtypes at High Gastric Cancer Risk: a Cluster-randomized Controlled Trial | not yet recruiting | N/A | 4,824 | Fudan UniversityOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT06943768 | Fecal DNA Methylation and Helicobacter Pylori Gastric Cancer Susceptibility Genes Test | not yet recruiting | — | 9,654 | Fudan UniversityOTHER | 0 | Jun 24, 2025 | clinicaltrials |
| NCT06871527 | Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer | not yet recruiting | Phase 1 / Phase 2 | 44 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT06858644 | Development of a Predictive Model for Gastric Cancer Peritoneal Metastasis and Cachexia Using BUB1 and Radiopathomics Data With Deep Learning(BUDDLE) | not yet recruiting | — | 500 | Qun ZhaoOTHER | 0 | Mar 5, 2025 | clinicaltrials |
| NCT06748508 | Comparing the Efficacy of Sintilimab Plus Nab-POF Regimen, Sintilimab Plus XELOX Chemotherapy, and Lenvatinib, Sintilimab Plus XELOX Chemotherapy in the Treatment of HER2-negative, Metastatic Gastric Cancer(FDZL-GC003) | not yet recruiting | Phase 2 | 141 | Fudan UniversityOTHER | 1 | Dec 27, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Jun 18, 2026source: clinicaltrials